|
62 Companies |
|
71 Products |
|
71 Products |
|
81 Mechanisms of Action |
|
10 Trials |
|
587 News |
|
| «12345678910111213» |
- | Zaltrap (ziv-aflibercept IV) / Sanofi
New P2 trial, Metastases: Ziv-Aflibercept Followed by Ziv-Aflibercept, Fluorouracil, and Leucovorin Calcium in Treating Patients With Stage IV Colorectal Cancer (clinicaltrials.gov) - Sep 9, 2014
P2, N=58, Not yet recruiting, Sponsor: University of Southern California
- Omegaven (omega-3 long-chain polyunsaturated fatty acids) / Fresenius Kabi
New P4 trial: EMPIRE: Effect of Omega-3 Fatty Acids on the Perioperative Immune Response and Erythrocyte Function (clinicaltrials.gov) - Sep 5, 2014
P4, N=44, Not yet recruiting, Sponsor: Medical Center Alkmaar
- Trial suspension, Trial primary completion date: A Pilot Trial of Interpersonal Psychotherapy for the Treatment of Depression in Patients With Prostate, Colorectal, Lung and Pancreatic Cancer (clinicaltrials.gov) - Sep 4, 2014
P=N/A, N=20, Suspended, Sponsor: New York State Psychiatric Institute
Recruiting --> Suspended | Trial primary completion date: Aug 2015 --> Aug 2016
- ||| Avastin (bevacizumab) / Roche
Clinical: Follow up to the AVANT Study up to 8 and 10 Years (Median Follow up) in Patients With Colon Carcinoma (clinicaltrials.gov) - Aug 29, 2014
P=N/A, N=3451, Not yet recruiting, Sponsor: Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)
- | New P2 trial: Latino Peers as Patient Navigators for Colon Cancer Screening (clinicaltrials.gov) - Aug 27, 2014
P2, N=130, Recruiting, Sponsor: Mount Sinai School of Medicine
- linifanib (ABT-869) / AbbVie
Enrollment change, Trial termination, Trial primary completion date, Metastases: Linifanib in Treating Patients With Advanced, Refractory Colorectal Cancer (clinicaltrials.gov) - Aug 26, 2014
P2, N=30, Terminated, Sponsor: Vanderbilt-Ingram Cancer Center
Recruiting --> Suspended | Trial primary completion date: Aug 2015 --> Aug 2016 N=57 --> 30 | Suspended --> Terminated | Trial primary completion date: Mar 2015 --> May 2012; Interim analysis determined the study did not meet criteria to proceed
- || Enrollment change: A Non-Interventional Study of the Occurrence Rate of Non-Small Cell Lung Cancer, Colon Cancer, Breast Cancer, Gastric Cancer and Malignant Melanoma in Turkey, and Diagnosis and Treatment Characteristics (clinicaltrials.gov) - Aug 21, 2014
P=N/A, N=25000, Recruiting, Sponsor: Hoffmann-La Roche
N=57 --> 30 | Suspended --> Terminated | Trial primary completion date: Mar 2015 --> May 2012; Interim analysis determined the study did not meet criteria to proceed N=10000 --> 25000
- ||| Avastin (bevacizumab) / Roche, GI-4000 / ImmunityBio
Enrollment closed, Metastases: A Pilot Trial of GI-4000 Plus Bevacizumab and Either FOLFOX or FOLFIRI (clinicaltrials.gov) - Aug 15, 2014
P2, N=52, Active, not recruiting, Sponsor: Georgetown University
N=10000 --> 25000 Recruiting --> Active, not recruiting
- Trial completion, Enrollment change: Comparing Water Immersion and Water Exchange Methods During Minimally Sedated Colonoscopy (clinicaltrials.gov) - Aug 15, 2014
P=N/A, N=270, Completed, Sponsor: Dalin Tzu Chi General Hospital
Recruiting --> Active, not recruiting Recruiting --> Completed | N=180 --> 270
- Avastin (bevacizumab) / Roche
Trial primary completion date, Combination therapy, Metastases: Sorafenib Tosylate, Bevacizumab, Irinotecan Hydrochloride, Leucovorin Calcium, and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Aug 1, 2014
P1, N=18, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed | N=180 --> 270 Trial primary completion date: May 2013 --> Aug 2014
- Trial primary completion date: Indocyanine Green (ICG) in the ex Vivo Detection of Sentinel Lymph Node (SLN)in Colon Cancer (clinicaltrials.gov) - Jul 24, 2014
P=N/A, N=20, Recruiting, Sponsor: Jules Bordet Institute
Trial primary completion date: May 2013 --> Aug 2014 Trial primary completion date: Mar 2014 --> Oct 2014
- Trial completion, HEOR: HOPE: Quality of Life and Survivorship Care in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy (HIPEC) (clinicaltrials.gov) - Jul 23, 2014
P=N/A, N=10, Completed, Sponsor: Comprehensive Cancer Center of Wake Forest University
Trial primary completion date: Mar 2014 --> Oct 2014 Active, not recruiting --> Completed
- Avastin (bevacizumab) / Roche
Trial primary completion date, Surgery, Metastases: Combination Chemotherapy and Bevacizumab Before Surgery and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Jul 21, 2014
P2, N=25, Active, not recruiting, Sponsor: City of Hope Medical Center
Active, not recruiting --> Completed Trial primary completion date: Apr 2017 --> Oct 2017
- Zaltrap (ziv-aflibercept IV) / Sanofi
Enrollment change, Trial withdrawal, Trial primary completion date, Combination therapy, Metastases: Short-Infusion Ziv-aflibercept in Treating Patients With Metastatic Colorectal Cancer Receiving Combination Chemotherapy (clinicaltrials.gov) - Jul 21, 2014
P=N/A, N=0, Withdrawn, Sponsor: City of Hope Medical Center
Trial primary completion date: Apr 2017 --> Oct 2017 N=30 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Jan 2016 --> Jul 2014
- Clinical: Peer Patient Navigation for Colon Cancer Screening (clinicaltrials.gov) - Jul 21, 2014
P=N/A, N=800, Completed, Sponsor: Mount Sinai School of Medicine
- ||||| rosuvastatin / Generic mfg.
Enrollment closed, Enrollment change, Trial primary completion date, Surgery: Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery (clinicaltrials.gov) - Jul 21, 2014
P3, N=406, Active, not recruiting, Sponsor: National Surgical Adjuvant Breast and Bowel Project (NSABP)
N=30 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Jan 2016 --> Jul 2014 Recruiting --> Active, not recruiting | N=1740 --> 406 | Trial primary completion date: Mar 2022 --> Mar 2015
- ||||||| Kepivance (palifermin) / SOBI, Amgen
Trial completion, Metastases: A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Stage 2B or 3 Locally Advanced, Colon Cancer (clinicaltrials.gov) - Jul 15, 2014
P2/3, N=100, Completed, Sponsor: Amgen
Recruiting --> Active, not recruiting | N=1740 --> 406 | Trial primary completion date: Mar 2022 --> Mar 2015 Active, not recruiting --> Completed
- GI-6301 / BMS
Enrollment closed: Cancer Vaccine Targeting Brachyury Protein in Tumors (clinicaltrials.gov) - Jul 2, 2014
P1, N=38, Active, not recruiting, Sponsor: GlobeImmune
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||| Trial completion: PILLAR II: Perfusion Assessment in Laparoscopic Left Anterior Resection (clinicaltrials.gov) - Jul 1, 2014
P1, N=147, Completed, Sponsor: Novadaq Technologies Inc.
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- || Biomarker, Enrollment change, Metastases: Study of a Screening Blood Test to Determine Patients' Potential Risk of Adenomatous or Advanced Colon Polyps (ACPs) (clinicaltrials.gov) - Jun 26, 2014
P=N/A, N=72, Completed, Sponsor: Mayo Clinic
Active, not recruiting --> Completed N=200 --> 72
- ||| Biomarker, Trial completion, Enrollment change, Metastases: Study of a Screening Blood Test to Determine Patients' Potential Risk of Adenomatous or Advanced Colon Polyps (ACPs) (clinicaltrials.gov) - Jun 26, 2014
P=N/A, N=72, Completed, Sponsor: Mayo Clinic
N=200 --> 72 Enrolling by invitation --> Completed | N=200 --> 72
- Recentin (cediranib) / AstraZeneca, RG4733 / Roche
Trial primary completion date, Metastases: Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors (clinicaltrials.gov) - Jun 19, 2014
P1, N=50, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Enrolling by invitation --> Completed | N=200 --> 72 Trial primary completion date: May 2014 --> Aug 2014
- Enrollment change, HEOR, Surgery: CHIRCOL: Laparoscopic Surgery Equivalent to Open Surgery in Right Colon Cancer Surgery? (clinicaltrials.gov) - Jun 17, 2014
P=N/A, N=150, Recruiting, Sponsor: Assistance Publique - H
Trial primary completion date: May 2014 --> Aug 2014 N=300 --> 150
- Trial primary completion date: Genetic Investigation of Solid Tumors Cohort (clinicaltrials.gov) - Jun 13, 2014
P=N/A, N=25, Completed, Sponsor: Scripps Translational Science Institute
N=300 --> 150 Trial primary completion date: Dec 2014 --> May 2014
- Enrollment change: Genetic Investigation of Solid Tumors Cohort (clinicaltrials.gov) - Jun 13, 2014
P=N/A, N=25, Completed, Sponsor: Scripps Translational Science Institute
Trial primary completion date: Dec 2014 --> May 2014 N=5000 --> 25
- Trial completion: Genetic Investigation of Solid Tumors Cohort (clinicaltrials.gov) - Jun 13, 2014
P=N/A, N=25, Completed, Sponsor: Scripps Translational Science Institute
N=5000 --> 25 Active, not recruiting --> Completed
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly
Trial primary completion date, Combination therapy, Metastases: Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer (clinicaltrials.gov) - Jun 12, 2014
P1/2, N=66, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Trial primary completion date: Jul 2008 --> Oct 2007
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly
Trial completion, Combination therapy, Metastases: Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer (clinicaltrials.gov) - Jun 9, 2014
P1/2, N=66, Completed, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jul 2008 --> Oct 2007 Recruiting --> Completed
- Mektovi (binimetinib) / Ono Pharma, Pierre Fabre, Pfizer
Trial initiation date, Combination therapy, Metastases: MEK Inhibitor MEK162 in Combination With Leucovorin Calcium, Fluorouracil, and Oxaliplatin in Treating Patients With Advanced Metastatic Colorectal Cancer (clinicaltrials.gov) - Jun 3, 2014
P1, N=34, Recruiting, Sponsor: City of Hope Medical Center
Recruiting --> Completed Initiation date: Mar 2014 --> Jun 2014
- Mektovi (binimetinib) / Ono Pharma, Pierre Fabre, Pfizer
Enrollment open, Combination therapy, Metastases: MEK Inhibitor MEK162 in Combination With Leucovorin Calcium, Fluorouracil, and Oxaliplatin in Treating Patients With Advanced Metastatic Colorectal Cancer (clinicaltrials.gov) - Jun 3, 2014
P1, N=34, Recruiting, Sponsor: City of Hope Medical Center
Initiation date: Mar 2014 --> Jun 2014 Not yet recruiting --> Recruiting
- | Arenegyr (NGR-hTNF) / AGC Biologics
Trial completion, Combination therapy, Metastases: NGR-hTNF Administered in Combination With a Standard Oxaliplatin Based Regimen in Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - May 28, 2014
P2, N=24, Completed, Sponsor: MolMed S.p.A.
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- IO biomarker: MOST: Mediterranean Oncology Senior Tests (clinicaltrials.gov) - May 26, 2014
P=N/A, N=180, Active, not recruiting, Sponsor: Association Sud pour la Recherche en Oncog
- Erbitux (cetuximab) / Eli Lilly, Koselugo (selumetinib) / Merck (MSD), AstraZeneca
Trial completion, Combination therapy: Selumetinib and Cetuximab in Treating Patients With Refractory Solid Tumors (clinicaltrials.gov) - May 19, 2014
P1, N=33, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial primary completion date: Educational CD-ROM Compared With Standard Informed Consent for Patients With Colorectal Cancer or a Family History of Colorectal Cancer (clinicaltrials.gov) - May 14, 2014
P=N/A, N=239, Completed, Sponsor: Fox Chase Cancer Center
Active, not recruiting --> Completed Trial primary completion date: Dec 2014 --> Nov 2011
- Trial completion: Educational CD-ROM Compared With Standard Informed Consent for Patients With Colorectal Cancer or a Family History of Colorectal Cancer (clinicaltrials.gov) - May 14, 2014
P=N/A, N=239, Completed, Sponsor: Fox Chase Cancer Center
Trial primary completion date: Dec 2014 --> Nov 2011 Active, not recruiting --> Completed
- |||| rosuvastatin / Generic mfg.
Trial primary completion date, Surgery: Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery (clinicaltrials.gov) - May 6, 2014
P3, N=1740, Recruiting, Sponsor: National Surgical Adjuvant Breast and Bowel Project (NSABP)
Active, not recruiting --> Completed Trial primary completion date: Jan 2020 --> Mar 2022
- Clinical: Low Glycemic Load Diet in Patients With Stage I-III Colon Cancer (clinicaltrials.gov) - Apr 30, 2014
P=N/A, N=72, Not yet recruiting, Sponsor: Case Comprehensive Cancer Center
- dasatinib / Generic mfg.
Trial initiation date, Metastases: Dasatinib in Treating Patients With Previously Treated Metastatic Colorectal Cancer (clinicaltrials.gov) - Apr 29, 2014
P2, N=19, Completed, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jan 2020 --> Mar 2022 Initiation date: May 2007 --> Jul 2007
- dasatinib / Generic mfg.
Trial completion, Metastases: Dasatinib in Treating Patients With Previously Treated Metastatic Colorectal Cancer (clinicaltrials.gov) - Apr 29, 2014
P2, N=19, Completed, Sponsor: National Cancer Institute (NCI)
Initiation date: May 2007 --> Jul 2007 Active, not recruiting --> Completed
- |||| Enrollment open: Polyphenon E in Treating Patients With High-Risk of Colorectal Cancer (clinicaltrials.gov) - Apr 27, 2014
P2, N=120, Recruiting, Sponsor: Mayo Clinic
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Farydak (panobinostat) / Secura Bio
Trial suspension, Metastases: Panobinostat and Fluorouracil Followed By Leucovorin Calcium in Treating Patients With Stage IV Colorectal Cancer Who Did Not Respond to Previous Fluorouracil-Based Chemotherapy (clinicaltrials.gov) - Apr 23, 2014
P1, N=50, Suspended, Sponsor: University of Southern California
Not yet recruiting --> Recruiting Recruiting --> Suspended
- Jingzhuda (entinostat) / EOC Pharma, EddingPharm
Trial completion date, Metastases: Azacitidine and Entinostat in Treating Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Apr 21, 2014
P2, N=47, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
- Jingzhuda (entinostat) / EOC Pharma, EddingPharm
Enrollment closed, Metastases: Azacitidine and Entinostat in Treating Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Apr 21, 2014
P2, N=47, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Suspended Completed --> Active, not recruiting
- Clinical: Full Spectrum vs. Standard Forward-viewing Colonoscopy (clinicaltrials.gov) - Apr 17, 2014
P=N/A, N=120, Not yet recruiting, Sponsor: Attikon Hospital
- Clinical: Code Barre: Simultaneaous Detection of Quantitative Somatic Alterations Using the Qantitative Multiplex Pcr of Short Fluorescent Fragments Method (QMPSF) in Stage II-III Colon Cancer: a Prospective Study (clinicaltrials.gov) - Apr 8, 2014
P=N/A, N=401, Completed, Sponsor: University Hospital, Rouen
- New P1 trial, Metastases: Irinotecan-Eluting Beads in Treating Patients With Refractory Metastatic Colon or Rectal Cancer That Has Spread to the Liver (clinicaltrials.gov) - Apr 8, 2014
P1, N=30, Not yet recruiting, Sponsor: Fox Chase Cancer Center
- veliparib (ABT-888) / AbbVie
Enrollment change, Combination therapy, BRCA Biomarker, PARP Biomarker, Metastases: Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors (clinicaltrials.gov) - Mar 31, 2014
P1, N=16, Terminated, Sponsor: National Cancer Institute (NCI)
Completed --> Active, not recruiting N=36 --> 16
- Vectibix (panitumumab) / Amgen
Enrollment closed: Neoadjuvant Treatment of Colon Cancer (clinicaltrials.gov) - Mar 27, 2014
P2, N=76, Active, not recruiting, Sponsor: Vejle Hospital
N=36 --> 16 Recruiting --> Active, not recruiting
- |||| Vectibix (panitumumab) / Amgen
Trial completion: STEPP: Skin Toxicity Treatment in Metastatic Colorectal Cancer (mCRC) Patients Receiving Panitumumab + Irinotecan-based Therapy (clinicaltrials.gov) - Mar 27, 2014
P2, N=95, Completed, Sponsor: Amgen
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Enrollment change, Compliance: Johns Hopkins Interactive eGuide to Colonoscopy and Ipad Office Education to Improve Colonoscopy (clinicaltrials.gov) - Mar 25, 2014
P=N/A, N=40, Completed, Sponsor: Johns Hopkins University
Active, not recruiting --> Completed N=600 --> 40